Axsome Therapeutics, Inc. (AXSM)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Axsome Therapeutics, Inc. reported revenue of $638.50M, up 65.5% from the prior year. The company ran a net loss, with a net margin of -28.7%. It held $689.80M in total assets against $601.51M in total liabilities.
Key ratios (FY2025)
-26.1%
Operating margin
-28.7%
Net margin
-207.5%
Return on equity
+65.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $638.50M | $385.69M | $270.60M | $50.04M | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | $5.20M | — | — | — | — | — | — |
| Operating Income | -$166.76M | -$280.56M | -$231.82M | -$179.80M | -$124.71M | -$99.14M | -$67.25M | -$32.85M | -$27.16M | -$27.54M |
| Net Income | -$183.17M | -$287.22M | -$239.24M | -$187.13M | -$130.40M | -$102.90M | -$68.35M | -$30.97M | -$28.94M | -$27.20M |
| EPS (Diluted) | $-3.68 | $-5.99 | $-5.27 | $-4.60 | $-3.47 | $-2.77 | — | — | — | — |
| Total Assets | $689.80M | $568.50M | $588.24M | $331.48M | $87.79M | $186.13M | $220.55M | $15.38M | $35.56M | $38.21M |
| Total Liabilities | $601.51M | $511.48M | $397.26M | $221.92M | $72.15M | $72.34M | $41.83M | $14.44M | $18.84M | $16.64M |
| Shareholders' Equity | $88.30M | $57.02M | $190.98M | $109.56M | $15.63M | $113.79M | $178.72M | $937.9K | $16.72M | $21.57M |
| Cash & Equivalents | $322.93M | $315.35M | $386.19M | $200.84M | $86.47M | $183.88M | $219.97M | — | — | — |
| Operating Cash Flow | -$93.41M | -$128.41M | -$145.08M | -$116.51M | -$108.23M | -$78.46M | -$46.38M | -$30.05M | -$26.47M | -$21.28M |
| Capital Expenditures | $480.0K | $270.0K | $582.0K | $702.0K | $308.0K | $45.9K | $16.1K | $32.7K | $9.9K | $104.6K |
| Shares Outstanding | 50.88M | 48.67M | 47.35M | 43.50M | 37.82M | 37.37M | 36.93M | 30.09M | 25.49M | 19.15M |